OncoCyte (NAS:OCX) ROE %

: -45.26% (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. OncoCyte's annualized net income for the quarter that ended in Sep. 2022 was $-37.33 Mil. OncoCyte's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $82.48 Mil. Therefore, OncoCyte's annualized ROE % for the quarter that ended in Sep. 2022 was -45.26%.

The historical rank and industry rank for OncoCyte's ROE % or its related term are showing as below:

OCX' s ROE % Range Over the Past 10 Years
Min: -402.61 Med: -130.91 Max: -93.07
Current: -82.55

During the past 9 years, OncoCyte's highest ROE % was -93.07%. The lowest was -402.61%. And the median was -130.91%.

OCX's ROE % is ranked worse than
73.75% of 1455 companies
in the Biotechnology industry
Industry Median: -42.71 vs OCX: -82.55

OncoCyte ROE % Historical Data

The historical data trend for OncoCyte's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROE %

-271.64

-402.61

-130.91

-93.07

-129.88

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROE %																-54.65	-174.45	-67.38	-45.77	-45.26

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

OncoCyte ROE % Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's ROE % distribution charts can be found below:

* The bar in red indicates where OncoCyte's ROE % falls in comparison to its industry or sector. The grey bar indicates the ROE %'s extreme value range as defined by GuruFocus.

OncoCyte ROE % Calculation

OncoCyte's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %	=	Net Income (A: Dec. 2021 )	/	( (Total Stockholders Equity (A: Dec. 2020 )	+	Total Stockholders Equity (A: Dec. 2021 ))	/ count )
	=	-64.097	/	( (33.483	+	65.217)	/ 2 )
	=	-64.097	/	49.35
	=	-129.88 %

OncoCyte's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %	=	Net Income (Q: Sep. 2022 )	/	( (Total Stockholders Equity (Q: Jun. 2022 )	+	Total Stockholders Equity (Q: Sep. 2022 ))	/ count )
	=	-37.332	/	( (88.097	+	76.857)	/ 2 )
	=	-37.332	/	82.477
	=	-45.26 %

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.

OncoCyte (NAS:OCX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

	ROE %		(Q: Sep. 2022 )
=	Net Income	/	Total Stockholders Equity
=	-37.332	/	82.477
=	(Net Income / Revenue )	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-37.332 / 4.068)	*	(4.068 / 164.1975)	*	(164.1975 / 82.477)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-917.7 %	*	0.0248	*	1.9908
=	ROA %	*	Equity Multiplier
=	-22.76 %	*	1.9908
=	-45.26 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

	ROE %		(Q: Sep. 2022 )
=	Net Income	/	Total Stockholders Equity
=	-37.332	/	82.477
=	(Net Income / Pre-Tax Income)	*	(Pre-Tax Income / Operating Income)	*	(Operating Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-37.332 / -37.332)	*	(-37.332 / -59.22)	*	(-59.22 / 4.068)	*	(4.068 / 164.1975)	*	(164.1975 / 82.477)
=	Tax Burden	*	Interest Burden	*	Operating Margin %	*	Asset Turnover	*	Equity Multiplier
=	1	*	0.6304	*	-1455.75 %	*	0.0248	*	1.9908
=	-45.26 %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
^* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

OncoCyte ROE % Related Terms

Thank you for viewing the detailed overview of OncoCyte's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » ROE %

Comparable Companies

Traded in Other Exchanges

0KCC:UK 7OC:Germany 7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Paulsen Gisela	officer: Chief Operating Officer	5505 ENDEAVOR LANE MADISON WI 53719
Yu Li	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE. NEWPORT BEACH CA 92660
Carter Jennifer L.	director	C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Ross Douglas T.	officer: Chief Medical Officer	15 CUSHING IRVINE CA 92618
Kamen Efrem	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011
Kalajian Tony T	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Griffith Melinda	director	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Sundar Padma	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Andrews Ronald Asbury	director	5791 VAN ALLEN WAY CARLSBAD CA 92008
Parker Albert P	officer: Chief Operating Officer	C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S	officer: Chief Financial Officer	ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Hesterberg Lyndal K.	officer: Sr VP, Research & Development	1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Bailey Don M	director	1300 N. KELLOGG DRIVE SUITE D ANAHEIM CA 92607
Bradsher Neal C	10 percent owner